B lymphocytes from patients with a hypomorphic mutation in STAT3 resist epstein-barr virus-driven cell proliferation

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 516-524

  Koganti, Siva ^a   de la Paz, Amanda ^b   Freeman, Alexandra F ^c   Bhaduri McIntosh, Sumita ^a,d  

^a Renaissance School of Medicine at Stony Brook University   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 2; STAT3 PROTEIN;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; EPSTEIN BARR VIRUS; FEMALE; GENE MUTATION; HUMAN; HYPER IGE SYNDROME; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; STAT3 GENE; UPREGULATION; VIRUS ONCOGENE; YOUNG ADULT;

ADOLESCENT; ADULT; B-LYMPHOCYTES; BASE SEQUENCE; CELL PROLIFERATION; CHILD; DNA PRIMERS; HERPESVIRUS 4, HUMAN; HUMANS; MIDDLE AGED; MUTATION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA, MESSENGER; S PHASE; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84890889458     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02601-13     Document Type: Article

References (47)

1. Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M. 2009. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83:7749-7760. http://dx.doi.org/10.1128/JVI.00108-09.
2. Shannon-Lowe C, Rowe M. 2011. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog. 7:e1001338. http://dx.doi.org/10.1371/journal.ppat.1001338.
3. Thorley-Lawson DA, Gross A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337. http://dx.doi.org/10.1056/NEJMra032015.
4. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. http://dx.doi.org/10.1038/nrc1452.
5. Heslop HE, Brenner MK, Rooney CM. 1994. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331:679-680. http://dx.doi .org/10.1056/NEJM199409083311017.
6. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al. 1994. Infusions of donor leukocytes to treat Epstein-Barr virusassociated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185-1191. http://dx.doi.org/10 .1056/NEJM199404283301703.
7. Saha A, Kaul R, Murakami M, Robertson ES. 2010. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol. Ther. 10:961-978. http://dx.doi.org/10.4161/cbt.10.10 .13923.
8. Sompallae R, Callegari S, Kamranvar SA, Masucci MG. 2010. Transcription profiling of Epstein-Barr virus nuclear antigen (EBNA)-1 expressing cells suggests targeting of chromatin remodeling complexes. PLoS One 5:e12052. http://dx.doi.org/10.1371/journal.pone.0012052.
9. Thorley-Lawson DA, Mann KP. 1985. Early events in Epstein-Barr virus infection provide a model for B cell activation. J. Exp. Med. 162:45-59. http://dx.doi.org/10.1084/jem.162.1.45.
10. Darnell JE, Jr. 1997. STATs and gene regulation. Science 277:1630-1635. http://dx.doi.org/10.1126/science.277.5332.1630.
11. Darnell JE, Jr. 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2:740-749. http://dx.doi.org/10.1038/nrc906.
12. Yang J, Stark GR. 2008. Roles of unphosphorylated STATs in signaling. Cell Res. 18:443-451. http://dx.doi.org/10.1038/cr.2008.41.
13. Yu H, Jove R. 2004. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4:97-105. http://dx.doi.org/10.1038/nrc1275.
14. Nepomuceno RR, Snow AL, Robert Beatty P, Krams SM, Martinez OM. 2002. Constitutive activation of Jak/STAT proteins in Epstein-Barr virusinfected B-cell lines from patients with posttransplant lymphoproliferative disorder. Transplantation 74:396-402. http://dx.doi.org/10.1097/00007890-200208150-00017.
15. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65:939-947. http://cancerres.aacrjournals.org/content/65/3/939.long.
16. Zhang L, Hong K, Zhang J, Pagano JS. 2004. Multiple signal transducers and activators of transcription are induced by EBV LMP-1. Virology 323: 141-152. http://dx.doi.org/10.1016/j.virol.2004.03.007.
17. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-1619. http://dx.doi.org/10.1056/NEJMoa073687.
18. Freeman AF, Holland SM. 2009. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr. Res. 65:32R-37R. http://dx.doi.org/10.1203/PDR.0b013e31819dc8c5.
19. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova JL, Cook MC, Tangye SG. 2010. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207: 155-171. http://dx.doi.org/10.1084/jem.20091706.
20. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205:1551-1557. http://dx.doi.org/10.1084/jem.20080218.
21. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. 2008. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-776. http://dx.doi.org/10.1038/nature06764.
22. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, Douek DC, Fahle GH, Cohen JI, Holland SM, Milner JD. 2011. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35:806-818. http://dx .doi.org/10.1016/j.immuni.2011.09.016.
23. Tangye SG, Cook MC, Fulcher DA. 2009. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J. Immunol. 182:21-28. http://www.jimmunol.org/content/182/1/21.full.
24. Oh HM, Oh JM, Choi SC, Kim SW, Han WC, Kim TH, Park DS, Jun CD. 2003. An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif. 36:191-197. http://dx.doi.org/10.1046/j.1365-2184.2003.00276.x.
25. Henle W, Henle GE, Horwitz CA. 1974. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum. Pathol. 5:551-565. http://dx.doi.org/10.1016/S0046-8177(74)80006-7.
26. Hui-Yuen J, McAllister S, Koganti S, Hill E, Bhaduri-McIntosh S. 2011. Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J. Exp. http://dx.doi.org/10.3791/3321.
27. Kremmer E, Kranz BR, Hille A, Klein K, Eulitz M, Hoffmann-Fezer G, Feiden W, Herrmann K, Delecluse HJ, Delsol G, Bornkamm GW, Mueller-Lantzsch N, Grassert FA. 1995. Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). Virology 208:336-342. http://dx.doi.org/10.1006/viro.1995.1157.
28. Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G. 2008. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood 111:1334-1343. http://dx.doi.org/10.1182/blood-2007-07-101907.
29. Hill ER, Koganti S, Zhi J, Megyola C, Freeman AF, Palendira U, Tangye SG, Farrell PJ, Bhaduri-McIntosh S. 2013. Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes. J. Virol. 87:11438-11446. http://dx.doi.org/10.1128/JVI.01762-13.
30. Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri-McIntosh S. 2010. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J. Virol. 84:993-1004. http://dx.doi.org/10.1128/JVI .01745-09.
31. Kung CP, Meckes DG, Jr, Raab-Traub N. 2011. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J. Virol. 85:4399-4408. http://dx.doi.org/10.1128/JVI.01703-10.
32. Pigazzi M, Manara E, Baron E, Basso G. 2009. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 69:2471-2478. http://dx.doi.org/10.1158/0008-5472.CAN-08-3404.
33. Wen Z, Zhong Z, Darnell JE, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82:241-250. http://dx.doi.org/10.1016/0092-8674(95)90311-9.
34. Allday MJ, Crawford DH, Griffin BE. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70(Part 7):1755-1764. http://dx.doi.org/10.1099/0022-1317-70-7-1755.
35. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. 2009. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4:e7214. http://dx.doi.org/10.1371/journal .pone.0007214.
36. Megyola C, Ye J, Bhaduri-McIntosh S. 2011. Identification of a subpopulation of B cells that proliferates after infection with Epstein-Barr virus. Virol. J. 8:84. http://dx.doi.org/10.1186/1743-422X-8-84.
37. Ichiba M, Nakajima K, Yamanaka Y, Kiuchi N, Hirano T. 1998. Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J. Biol. Chem. 273:6132-6138. http://dx.doi.org/10.1074/jbc.273.11.6132.
38. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. 1996. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15:3651-3658.
39. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. 2010. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. U. S. A. 107:850-855. http://dx.doi.org/10.1073/pnas .0911948107.
40. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79:13993-14003. http://dx.doi.org/10.1128/JVI.79.22.13993-14003.2005.
41. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648. http://dx.doi.org/10.1038/379645a0.
42. Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT. 1985. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J. Immunol. 134:3007-3012.
43. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D, Thomas C, Hoarau C, Lebranchu Y, Stephan JL, Cazorla C, Aladjidi N, Micheau M, Tron F, Baruchel A, Barlogis V, Palenzuela G, Mathey C, Dominique S, Body G, Munzer M, Fouyssac F, Jaussaud R, Bader-Meunier B, Mahlaoui N, Blanche S, Debre M, Le Bourgeois M, Gandemer V, Lambert N, Grandin V, Ndaga S, Jacques C, Harre C, Forveille M, Alyanakian MA, Durandy A, Bodemer C, Suarez F, Hermine O, Lortholary O, Casanova JL, Fischer A, Picard C. 2012. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 91:e1-e19. http://dx.doi.org/10.1097/MD.0b013e31825f95b9.
44. King CA. 2013. Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28. J. Virol. 87:8779-8791. http://dx.doi.org/10.1128/JVI.02976-12.
45. Punjabi AS, Carroll PA, Chen L, Lagunoff M. 2007. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J. Virol. 81:2449-2458. http://dx.doi.org/10.1128/JVI.01769-06.
46. Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J, Arvin AM. 2012. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 109:600-605. http://dx.doi.org/10 .1073/pnas.1114232109.
47. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hayward SD. 2001. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J. Virol. 75:2929-2937. http://dx.doi.org/10.1128/JVI.75.6.2929-2937.2001.